Posted by Michael Wonder on 10 May 2024
Celltrion USA's adalimumab-aaty biosimilar to Humira now available at low wholesale acquisition cost
9 May 2024 - Adalimumab-aaty will be priced at an 85% discount to Humira (adalimumab).
Celltrion USA announced today that adalimumab-aaty, the company's high concentration (100 mg/mL) and citrate-free formulation biosimilar to Humira (adalimumab), is now available at a low wholesale acquisition cost.
